Cemiplimab
- Generic Name
- Cemiplimab
- Brand Names
- Libtayo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1801342-60-8
- Unique Ingredient Identifier
- 6QVL057INT
- Background
Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses.
...
- Indication
Cemiplimab is indicated to treat:
- Associated Conditions
- Locally Advanced Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Metastatic cutaneous squamous cell carcinoma, Recurrent Cervical Cancer, Metastatic Basal cell carcinoma
- Associated Therapies
- First Line Chemotherapy
A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 612
- Registration Number
- NCT04590326
- Locations
- 🇪🇸
Ciudad Universitaria, Madrid, Spain
🇪🇸Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM, Madrid, Spain
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Gulam Manji
- Target Recruit Count
- 10
- Registration Number
- NCT04543071
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Brown University, Providence, Rhode Island, United States
Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT04465487
- Locations
- 🇺🇸
Angeles Clinic and Research Institute - Clinic/Outpatient Facility, Los Angeles, California, United States
🇺🇸H.Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Silverback Therapeutics
- Target Recruit Count
- 58
- Registration Number
- NCT04460456
- Locations
- 🇺🇸
University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇦🇺Macquarie University Hospital Clinical Trials Unit, Sydney, New South Wales, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 10
- Registration Number
- NCT04387084
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 75
- Registration Number
- NCT04382898
- Locations
- 🇬🇧
Cancer Research UK Cambridge Centre, Cambridge, United Kingdom
🇬🇧University of Glasgow, Beatson WoS Cancer Centre, Glasgow, United Kingdom
🇺🇸University of Miami Hospital & Clinics /Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT04373083
Cemiplimab in AlloSCT/SOT Recipients With CSCC
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT04339062
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 34
- Registration Number
- NCT04315701
- Locations
- 🇺🇸
University of Nebraska, Omaha, Nebraska, United States
🇺🇸Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Vyriad, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT04291105
- Locations
- 🇺🇸
Atlantic Health, Morristown, New Jersey, United States
🇺🇸Mayo Clinical, Jacksonville, Florida, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.